DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Propranolol (Propranolol Hydrochloride) - Indications and Dosage

 
 



INDICATIONS AND USAGE

Hypertension

Propranolol hydrochloride extended-release capsules are indicated in the management of hypertension. It may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Propranolol hydrochloride extended-release capsules are not indicated in the management of hypertensive emergencies.

Angina Pectoris Due to Coronary Atherosclerosis

Propranolol hydrochloride extended-release capsules are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris.

Migraine

Propranolol hydrochloride extended-release capsules are indicated for the prophylaxis of common migraine headache. The efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not indicated for such use.

Hypertrophic Subaortic Stenosis

Propranolol hydrochloride extended-release capsules improve NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis.

DOSAGE AND ADMINISTRATION

General

Propranolol hydrochloride extended-release capsules provide propranolol hydrochloride in a sustained-release capsule for administration once daily. If patients are switched from propranolol hydrochloride tablets to propranolol hydrochloride extended-release capsules, care should be

taken to assure that the desired therapeutic effect is maintained. Propranolol hydrochloride extended-release capsules should not be considered a simple mg-for-mg substitute for propranolol hydrochloride tablets. Propranolol hydrochloride extended-release capsules have different kinetics and produces lower blood levels. Retitration may be necessary, especially to maintain effectiveness at the end of the 24-hour dosing interval.

Hypertension

The usual initial dosage is 80 mg propranolol hydrochloride extended-release capsules once daily, whether used alone or added to a diuretic. The dosage may be increased to 120 mg once daily or higher until adequate blood pressure control is achieved. The usual maintenance dosage is 120 to 160 mg once daily. In some instances a dosage of 640 mg may be required. The time needed for full hypertensive response to a given dosage is variable and may range from a few days to several weeks.

Angina Pectoris

Starting with 80 mg propranolol hydrochloride extended-release capsules once daily, dosage should be gradually increased at three- to seven-day intervals until optimal response is obtained. Although individual patients may respond at any dosage level, the average optimal dosage appears to be 160 mg once daily. In angina pectoris, the value and safety of dosage exceeding 320 mg per day have not been established.

If treatment is to be discontinued, reduce dosage gradually over a period of a few weeks (see “ WARNINGS ”).

Migraine

The initial oral dose is 80 mg propranolol hydrochloride extended-release capsules once daily. The usual effective dose range is 160 to 240 mg once daily. The dosage may be increased gradually to achieve optimal migraine prophylaxis. If a satisfactory response is not obtained within four to six weeks after reaching the maximal dose, propranolol hydrochloride extended-release capsule therapy should be discontinued. It may be advisable to withdraw the drug gradually over a period of several weeks depending on the patient's age, comorbidity, and dose of propranolol hydrochloride extended-release capsules.

Hypertrophic Subaortic Stenosis

The usual dosage is 80 to 160 mg propranolol hydrochloride extended-release capsules once daily.

HOW SUPPLIED

  •  

Propranolol hydrochloride extended-release capsules, USP are available as follows:

 

60 mg – Each #3 capsule with white opaque cap and yellow opaque body printed with

and 2778 on the cap and body in black ink contains 60 mg of propranolol hydrochloride, USP.  Capsules are supplied in bottles of 100 (NDC 0228-2778-11) with a child-resistant closure and 500 (NDC 0228-2778-50) without a child-resistant closure.

80 mg – Each #3 capsule with yellow opaque cap and yellow opaque body printed with

and 2779 on the cap and body in black ink contains 80 mg of propranolol hydrochloride, USP.  Capsules are supplied in bottles of 100 (NDC 0228-2779-11) with a child-resistant closure and 500 (NDC 0228-2779-50) without a child-resistant closure.

120 mg – Each #2 capsule with gray opaque cap and yellow opaque body printed with

and 2780 on the cap and body in black ink contains 120 mg of propranolol hydrochloride, USP.  Capsules are supplied in bottles of 100 (NDC 0228-2780-11) with a child-resistant closure and 500 (NDC 0228-2780-50) without a child-resistant closure.

160 mg – Each #1 capsule with gray opaque cap and gray opaque body printed with

and 2781 on the cap and body in black ink contains 160 mg of propranolol hydrochloride, USP.  Capsules are supplied in bottles of 100 (NDC 0228-2781-11) with a child-resistant closure and 500 (NDC 0228-2781-50) without a child-resistant closure.

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].

Protect from light, moisture, freezing, and excessive heat.

Dispense in a tight, light-resistant container as defined in the USP.

Manufactured by:

Actavis Elizabeth LLC

200 Elmora Avenue

Elizabeth, NJ 07207 USA

40-9084

Revised - June 2011

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017